Rabeprazole - Latest Advances

Impact of Yoga and Naturopathy in a Patient with Chronic Idiopathic Axonal Polyneuropathy Associated with Metabolic Syndrome and Rheumatoid Arthritis: A Case Report.

Journal: Advances in mind-body medicine

Published: November 11, 2025

Optimizing Proton-pump Inhibitor Therapy in Patients with Comorbidities Receiving Polypharmacy Treatment: Insights from Clinical Practice in India.

Journal: The Journal of the Association of Physicians of India

Published: October 16, 2025

Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH.

Journal: Molecular pharmaceutics

Published: October 08, 2025

Bismuth-Based quintuple therapy: a step beyond quadruple regimens in H. Pylori treatment and the impact of patient compliance.

Journal: BMC gastroenterology

Published: September 15, 2025

Efficacy of 10 days high-dose and double-dose rabeprazole-based concomitant therapy for Helicobacter pylori eradication among Lebanese population: a pilot randomized controlled trial.

Journal: BMC gastroenterology

Published: September 11, 2025

Comparative evaluation of pregnancy-related adverse events associated with proton pump inhibitors using the FDA adverse event reporting system database.

Journal: International journal of clinical pharmacy

Published: August 21, 2025

Vitamin B12 Deficiency Associated with Metformin and Proton Pump Inhibitors and Their Combinations: Results from a Disproportionality and Interaction Analysis.

Journal: Diseases (Basel, Switzerland)

Published: August 14, 2025

Exploring the Anticancer Potential of Proton Pump Inhibitors by Targeting GRP78 and V-ATPase: Molecular Docking, Molecular Dynamics, PCA, and MM-GBSA Calculations.

Journal: International journal of molecular sciences

Published: July 25, 2025

Mechanistic insights into the hepatoprotective role of rabeprazole against cyclophosphamide-induced hepatotoxicity via AMPK/SIRT1 activation and suppression of TLR4/NF-κB and MAPK pathways.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: July 24, 2025

Esomeprazole prevents oxaliplatin-induced peripheral neuropathy through inhibiting organic cation transporter 2 in mice.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: July 14, 2025

The Efficacy of Potassium-Competitive Acid Blocker Compared With Double Dose of Proton Pump Inhibitor in Patients With Refractory Gastro-Esophageal Reflux Disease: A Case-Control Study.

Journal: The Korean journal of helicobacter and upper gastrointestinal research

Published: July 10, 2025

Vonoprazan-minocycline dual therapy as a first-line treatment of Helicobacter pylori infection compared with empirical bismuth-containing quadruple therapy.

Journal: Therapeutic advances in gastroenterology

Published: June 18, 2025

Filters

Impact of Yoga and Naturopathy in a Patient with Chronic Idiopathic Axonal Polyneuropathy Associated with Metabolic Syndrome and Rheumatoid Arthritis: A Case Report.

Impact of Yoga and Naturopathy in a Patient with Chronic Idiopathic Axonal Polyneuropathy Associated with Metabolic Syndrome and Rheumatoid Arthritis: A Case Report.

Optimizing Proton-pump Inhibitor Therapy in Patients with Comorbidities Receiving Polypharmacy Treatment: Insights from Clinical Practice in India.

Optimizing Proton-pump Inhibitor Therapy in Patients with Comorbidities Receiving Polypharmacy Treatment: Insights from Clinical Practice in India.

Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH.

Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH.

Bismuth-Based quintuple therapy: a step beyond quadruple regimens in H. Pylori treatment and the impact of patient compliance.

Bismuth-Based quintuple therapy: a step beyond quadruple regimens in H. Pylori treatment and the impact of patient compliance.

Efficacy of 10 days high-dose and double-dose rabeprazole-based concomitant therapy for Helicobacter pylori eradication among Lebanese population: a pilot randomized controlled trial.

Efficacy of 10 days high-dose and double-dose rabeprazole-based concomitant therapy for Helicobacter pylori eradication among Lebanese population: a pilot randomized controlled trial.

Comparative evaluation of pregnancy-related adverse events associated with proton pump inhibitors using the FDA adverse event reporting system database.

Comparative evaluation of pregnancy-related adverse events associated with proton pump inhibitors using the FDA adverse event reporting system database.

Vitamin B12 Deficiency Associated with Metformin and Proton Pump Inhibitors and Their Combinations: Results from a Disproportionality and Interaction Analysis.

Vitamin B12 Deficiency Associated with Metformin and Proton Pump Inhibitors and Their Combinations: Results from a Disproportionality and Interaction Analysis.

Exploring the Anticancer Potential of Proton Pump Inhibitors by Targeting GRP78 and V-ATPase: Molecular Docking, Molecular Dynamics, PCA, and MM-GBSA Calculations.

Exploring the Anticancer Potential of Proton Pump Inhibitors by Targeting GRP78 and V-ATPase: Molecular Docking, Molecular Dynamics, PCA, and MM-GBSA Calculations.

Mechanistic insights into the hepatoprotective role of rabeprazole against cyclophosphamide-induced hepatotoxicity via AMPK/SIRT1 activation and suppression of TLR4/NF-κB and MAPK pathways.

Mechanistic insights into the hepatoprotective role of rabeprazole against cyclophosphamide-induced hepatotoxicity via AMPK/SIRT1 activation and suppression of TLR4/NF-κB and MAPK pathways.

Esomeprazole prevents oxaliplatin-induced peripheral neuropathy through inhibiting organic cation transporter 2 in mice.

Esomeprazole prevents oxaliplatin-induced peripheral neuropathy through inhibiting organic cation transporter 2 in mice.

The Efficacy of Potassium-Competitive Acid Blocker Compared With Double Dose of Proton Pump Inhibitor in Patients With Refractory Gastro-Esophageal Reflux Disease: A Case-Control Study.

The Efficacy of Potassium-Competitive Acid Blocker Compared With Double Dose of Proton Pump Inhibitor in Patients With Refractory Gastro-Esophageal Reflux Disease: A Case-Control Study.

Vonoprazan-minocycline dual therapy as a first-line treatment of Helicobacter pylori infection compared with empirical bismuth-containing quadruple therapy.

Vonoprazan-minocycline dual therapy as a first-line treatment of Helicobacter pylori infection compared with empirical bismuth-containing quadruple therapy.